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ABSTRACT 
 
 THE EFFECT OF EXERCISE AND CALORIC RESTRICTION ON 
CARDIAC NF-kB SIGNALING AND INFLAMMATION IN OTSUKA 
LONG-EVANS TOKUSHIMA FATTY (OLETF) RATS 
SEPTEMBER 2015 
ANGEL EXPEDITO BAEZ, B.S., UNIVERSITY OF MASSACHUSETTS   
M.S., UNIVERSITY OF MASSACHUSETTS AMHERST 
Directed By: Professor Sarah Witkowski 
 
Introduction: Cardiometabolic syndrome is considered a chronic low-grade 
inflammatory condition that affects various organs and tissues. Individuals with type 2 
diabetes mellitus (T2DM) and obesity are at an increased risk for developing the 
cardiometabolic syndrome and have greater rates of cardiovascular disease (CVD).  
These conditions are also associated with increased systemic and local inflammation and 
greater expression of pro-inflammatory markers such as monocyte chemoattractant 
protein 1 (MCP-1), tumor necrosis factor-α (TNF-α), and interleukin 1β (IL-1β) in many 
tissues.  The heart is adversely affected by the inflammation and metabolic changes 
induced by diabetes and obesity. Nuclear transcription factor kappa B (NF-κB) activity is 
known to be related to inflammation and cytokine production. However, there is limited 
information on whether NF-κB signaling and inflammation play a role in early cardiac 
pathogenesis related to obesity and diabetes and whether lifestyle changes known to 
prevent or treat these diseases are effective in the heart.  Purpose: Therefore, the purpose 
of this study was to compare the effect of exercise (EX) and caloric restriction (CR) to 
alter NF-κB signaling, inflammation, and markers of cardiac dysfunction in the heart of 
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20-week old Otsuka Long Evans Tokushima (OLETF) rats. Methods: Hearts of male 20 
week old OLETF rats from a previous study (Crissey et al., 2014) were collected for gene 
expression (RT-PCR), NF-κB activity, and markers of inflammation and immune cell 
infiltration. Results: There were no significant differences detected in markers of cardiac 
dysfunction including, α-MHC, β-MHC, ANP, BNP, COL1, COL3 (all p>0.05). Second, 
1-way ANOVA showed that there was trend for an overall effect of group (p=0.07) on 
NF-κB activation where CR tended to be greater compared to SED and WR (p=0.06). 
Finally, there were no significant differences between groups in inflammatory and 
immune cell markers; CD4, F4/80, CD68, IL-1β, MCP-1, TGFB1, and TNF-α (all 
p>0.05). Conclusion: This study shows that at 20 weeks, a time when OLETF animals 
exhibit characteristics of the metabolic syndrome such as hypertension, mild obesity, and 
increased insulin resistance, EX and CR do not reduce markers of cardiac dysfunction 
and inflammation, potentially because inflammation does not influence the heart at this 
early time period in the development of the disease.  Further, the trend of greater NF-κB 
activity in CR compared to EX and SED, needs further exploration. 
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CHAPTER 1 
INTRODUCTION 
 Public health currently faces two epidemics; obesity and type 2 diabetes mellitus 
(T2DM). Worldwide obesity has nearly doubled since 1980. Approximately 1.6 billion 
adults are overweight with close to 500 million being considered obese (WHO, 2011). 
About two-thirds of adults in the United States are considered overweight or obese. 
Along with the rise of adult obesity, childhood obesity in the US has tripled over the past 
three decades (Flegal et al., 2010; Kalaupahana et al., 2012). According to the World 
Health Organization, 382 million people worldwide are afflicted with diabetes and in the 
United States 18 million people suffer from this disease (WHO, 2011; CDC, 2009). In 
addition, 90% of individuals suffering from type 2 diabetes mellitus are obese or 
overweight and are at an increased risk for cardiovascular morbidity and mortality. 
Cardiovascular disease is the number 1 cause of death in obese and diabetic individuals 
(Ogden, 2009). 
 Obesity and T2DM are both chronic low-grade systemic inflammatory diseases. 
These inflammatory responses are due to changes in adipose tissue depots and immune 
cell infiltration that lead to expression of pro-inflammatory cytokines. These pro-
inflammatory cytokines are believed to play a role in inducing insulin resistance, lipid 
accumulation in non-adipose sites, and metabolic changes in various organs such as the 
liver, skeletal muscle, and the heart (Kalupahana et al., 2012; Kahn et al., 2006). These 
pro-inflammatory cytokines are detrimental to the myocardium and can lead to the 
development of cardiac dysfunction, fibrosis, cardiomyopathies, and eventually to heart 
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failure. However, lifestyle interventions, such as exercise or caloric restriction, may be 
able to improve these conditions and induce an anti-inflammatory state. Though there is 
limited information on the effect of these two treatments. 
 In this study, the inflammatory-related changes that occur in the myocardium of 
overweight and insulin resistant rats in response to exercise and caloric restriction were 
explored.   To determine if either intervention attenuated myocardial dysfunction and 
inflammatory signaling, an evaluation of activity of a major inflammatory transcription 
factor, nuclear factor kappa B (NF-κB) and inflammation-related gene expression in the 
heart was completed.  
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CHAPTER 2 
LITERATURE REVIEW 
2.1 Introduction 
 This literature review will detail cardiometabolic syndrome and two of the main 
factors affecting it: obesity and insulin resistance. Specifically, the role of inflammation 
on the myocardium will be highlighted. Nuclear factor kappa B (NF-κB) will be 
introduced for its role in inflammation related to cardiometabolic syndrome and lifestyle 
interventions of exercise and caloric restriction will be reviewed as methods to improve 
inflammatory-related myocardial dysfunction as defined by fibrosis and tissue damage. 
2.1.1 Cardiometabolic Syndrome 
 Cardiometabolic syndrome, commonly referred to as metabolic syndrome or 
Syndrome X, is a cluster of multiple cardiovascular, metabolic, pro-thrombotic, and 
inflammatory abnormalities, which cause disruptions in energy storage and utilization. 
These cardiovascular and metabolic disruptions, individually and together, lead to an 
increased risk in the development of cardiovascular disease (CVD) and stroke (Castro et 
al., 2003). Cardiometabolic syndrome is becoming a growing concern. Globally, an 
estimated 25% of the world population is believed to suffer from cardiometabolic 
syndrome. In the United States, this syndrome affects nearly 44% of the elderly 
population over the age of 50. Approximately one-third of the US population age 20 and 
above already exhibit the criteria for cardiometabolic syndrome (Ford ES, 2005).  
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Cardiometabolic syndrome is diagnosed when a patient exhibits three out of five 
co-occurring risk factors: 1) abdominal adiposity (obesity), 2) hypertension, 3) insulin 
resistance, 4) dyslipidemia, and 5) reduction in high density lipoprotein (HDL) (Hertle et 
al., 2014; Kaur, 2014). Individuals suffering from these risk factors, especially 
individuals suffering from obesity as well as insulin resistance, are more prone to 
manifest other components of the cardiometabolic syndrome such as: an increased 
inflammatory state, increased oxidative stress, microalbuminuria, an increased risk of 
developing type 2 diabetes mellitus (T2DM) and endothelial dysfunction (Isomaa et al., 
2001). 
Aside from physiological risk factors, environmental, personal, and genetic traits 
can also contribute to cardiometabolic syndrome. Indeed, sedentary lifestyle, excess 
energy intake, genetic susceptibility, and stress play a role in the development of 
cardiometabolic syndrome (Cameron et al, 2004). When genetic or environmental 
factors, such as physical inactivity, advancing age, and high saturated fat-simple 
carbohydrate diet (Western Diet) concomitantly occur alongside obesity, the 
cardiometabolic syndrome is exacerbated (Grundy, S 2006). These individuals are three 
times more likely to develop coronary heart disease (CHD) and stroke and have two 
times the risk of dying from a cardiovascular event (Kaur, 2014).  Thus, it is important to 
identify individuals at risk and establish early interventions that prevent the development 
of CVD, stroke and CHD. 
Cardiometabolic syndrome is a progressive disorder that worsens over time 
(Grundy, S 2006). The pathogenesis of cardiometabolic syndrome is known to include 
two related conditions; insulin resistance and obesity (Grundy et al., 2005). It is well 
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known that insulin resistance and obesity induce dysfunction and physiological damage 
to the myocardium and various tissues/organs. The cause of the dysfunction in multiple 
tissues and organs may be due to inflammation from excess adipose tissue, endothelial 
inflammation, and alterations in the metabolism of these various tissues/organs due to 
insulin resistance and adipose tissue (Romacho et al., 2014). 
Most studies evaluating the relationship between obesity, insulin resistance and 
myocardial dysfunction have used dramatic models of the disease or condition.  It is 
unknown what changes occur to the myocardium in early stages of obesity (overweight) 
or insulin resistance.  Understanding the early effects of obesity and insulin resistance on 
the heart and the influence of early lifestyle or pharmacological interventions can help 
prevent patients from developing T2DM and CVD. 
2.1.2 Obesity, Type 2 Diabetes Mellitus and Insulin Resistance 
 Although there are many factors that influence cardiometabolic syndrome, obesity 
and insulin resistance (which progresses to T2DM) are considered the main underlying 
causes and greatly influence changes in the heart. Obesity is defined as excess or increase 
in adiposity that is detrimental to an individual’s health and resulting in a body mass 
index (BMI) ≥ 30 kg/m2  (WHO, 2011). Obesity is a growing epidemic that is afflicting 
millions of people in the world and United States. Worldwide obesity has nearly doubled 
since 1980. Approximately 1.6 billion adults are overweight with close to 500 million 
being considered obese (WHO, 2011). About two-thirds of adults in the United States are 
considered overweight or obese. Along with the rise of adult obesity, childhood obesity 
in the US has tripled over the past three decades (Flegal et al., 2010; Kalaupahana et al., 
2012), highlighting the need to generate and evaluate effective therapies for the 
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condition. Obesity is considered the 5th leading cause of mortality worldwide (WHO, 
2011). In the United States alone, the estimated annual healthcare cost of treating obesity 
is approximately $147 billion dollars (CDC, 2011). Obese individuals are at an increased 
risk of non-communicable diseases such as various forms of cancer, diabetes, kidney 
diseases, and cardiovascular disease (WHO, 2011). Indeed, 70% of all CVD causes are 
related to obesity and 112,000 deaths each year are associated to obesity and CVD (NIH, 
2013). Therefore, prevention of obesity can help reduce the mortality and morbidity both 
of obesity and CVD and reduce the expense associated with treating these diseases. 
As with obesity, type 2 diabetes mellitus (T2DM) is another growing epidemic in 
the United States and around the world. Type 2 Diabetes Mellitus (referred to previously 
as non-insulin dependent diabetes or adult-onset diabetes) is a progressive metabolic 
disorder that is characterized by insulin resistance and dysfunction of pancreatic β-cells 
(Beck-Nielson et al., 1994).  According to the World Health Organization, 382 million 
people worldwide are afflicted with diabetes and it is projected to be the 7th leading cause 
of death by the year 2030 (WHO, 2013).  In the United States, the number of individuals 
suffering from diabetes have tripled between 1980 and 2008, increasing from 5.5 million 
to 18 million (CDC, 2009; Kalupahana et al., 2012). Cardiovascular disease (CVD) is the 
leading cause of death in individuals with type 2 diabetes mellitus (WHO, 2013; 
Kalupahana et al., 2012; Kahn et al., 2006).  
Both obesity and T2DM are chronic and complex diseases whose causes can also 
be attributed to genetic and environmental factors (Wang, Z & Nakayama, T., 2010).  
Both diseases are linked to one another as 35% of obese individuals suffer from diabetes 
while about 90% of diabetics are overweight or obese. Further, individuals who suffer 
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from T2DM and are obese or overweight are two to four times more likely to exhibit 
cardiovascular disease (Kalupahana et al., 2012). Insulin resistance appears to be the 
main pathophysiological link between obesity and diabetes. 
In the normal insulin response, during a fasting state, the liver produces glucose 
via gluconeogenesis and glycogenolysis as a means to maintain normal blood glucose 
concentrations. During the consumption of a meal, the intestines become a major site of 
glucose utilization, leading to increases in glucose availability to the pancreas. This in 
turn causes the pancreas to secrete insulin (Kalupahana et al., 2012).  Insulin allows many 
tissues and organs in the body to transport and utilize glucose for metabolism. Insulin 
helps maintain normoglycemia, especially in liver, cardiac, adipose, and skeletal tissues. 
After insulin is secreted, it plays an important role in inhibiting gluconeogenesis and 
glucogenolysis from the liver. This mechanism in turn causes the liver to undergo 
glycogen synthesis. In skeletal and cardiac tissue, insulin increases glucose uptake and 
utilization.  In adipose tissue, it inhibits lipolysis and increases the up-regulation of 
lipogenesis.  
Insulin resistance is defined as an impaired biological response of insulin-
sensitive tissues in the body to normal circulation of insulin in the blood, leading to 
uncontrollable blood sugar levels. When insulin resistance occurs, the normal tissue 
response to insulin is blunted (i.e. decreased insulin sensitivity) leading to relative 
hyperglycemia and an increase in plasma levels of free fatty acids (Olefsky and Glass, 
2010).  To compensate for the resulting hyperglycemia, the β-cells of the pancreas secrete 
more insulin. The increased secretion of insulin alleviates the relative hyperglycemia 
inducing systemic normoglycemia. However, over time, as insulin resistance in tissues 
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progresses, it can lead to pancreatic β-cell dysfunction and failure.  With more circulating 
insulin, lipogenesis continues, leading to increases in fat tissue.  Another consequence of 
insulin resistance is propagation to a pro-inflammatory state (Stumvoll et al., 2005). Early 
studies found that obesity and the release of cytokines from adipose tissue plays a major 
role in the development of insulin resistance, known as obesity-related insulin resistance. 
2.1.3 Inflammation, Insulin Resistance and Obesity 
Previously thought to be inert and passive depots for lipid storage, an energy-rich 
substrate, adipose tissue and adipocytes were discovered to be a major active endocrine 
organ responsible for secreting bioactive factors called adipokines (Trayhurn & Wood, 
2004). In 1994, Zhang et al., cloned and sequenced the mouse ob gene and human 
homologue, leading to the discovery that this gene encoded a 4.5 kilobase (kb) adipose 
tissue messenger RNA that would become known as leptin, thereby identifying adipose 
tissue as a major endocrine organ. Adipokines are cell signaling proteins released from 
adipose tissue, consisting of classical cytokines and chemokines such as tumor necrosis 
factor-α (TNF-α) and interleukins (eg., IL-6, IL-1β, etc.), vasoactive and coagulation 
factors, and regulators of lipoprotein metabolism, among others (Mohamed-Ali et al., 
1998). It was through this adipokine secretion, that adipocytes and adipose tissue were 
discovered to play a central role in a complex and multidirectional network of autocrine, 
paracrine, and endocrine crosstalk between organs and tissues such as liver, skeletal 
muscle, pancreas, and heart (Romacho et al., 2014).  Adipokines can act locally through 
autocrine and paracrine signaling within the adipose tissue as a way to regulate local 
metabolism. They can also have downstream effects through systemic circulation via 
endocrine signaling. Adipokines play a vital role in maintaining insulin sensitivity, 
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inflammation, regulation of food intake and body weight, and coagulation or vascular 
function (Trayhurn & Wood, 2004; Guzik et al., 2006).  
The hypertrophy and hyperplasia of the visceral adipose tissue network due to 
insulin resistance and obesity leads to localized inflammatory responses. Inflammation is 
defined as a series of cellular and humoral reactions meant to defend the body from 
various insults such as infections or tissue damage. The ultimate goal of inflammation is 
to restore function and morphological integrity of the affected tissues (Lee & Lee 2014; 
Cildir et al., 2013). Inflammation is characterized by increases in local and systemic 
cytokine levels along with increased number of infiltrating immune cells. These immune 
cells are the first responders in such events. Neutrophils play an important role during 
acute phases of inflammation by initiating the immune response, while macrophages take 
the stage in more chronic conditions (Lee & Lee, 2014; Mraz & Haluzik, 2014).  
 Adipose tissue inflammation in obesity has been characterized by macrophage 
infiltration, which influences the changes in secretion of pro- and anti-inflammatory 
cytokines. Weisburg et al. (2003) used 24 mice with varying degrees of adiposity due to 
sex, diet, and obesity-related mutations such as agouti (Ay) and obese (Lepob) to assess 
gene expression in perigonadal, perirenal, mesenteric, and subcutaneous adipose tissues 
and the potential points of origin. In addition, human abdominal subcutaneous adipose 
tissue samples of lean, overweight, and obese subjects were collected. The researchers 
used microarrays, PCR, and immunohistochemistry and found over 1,304 transcripts that 
were correlated significantly with body mass, an indirect indicator of adiposity. A large 
portion of these transcripts encode proteins that are characteristic of macrophages. These 
results were further supported by histology data showing macrophage and immune cell 
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infiltration both in mice and human adipose tissues. These data confirmed that 
macrophage infiltration correlates with both BMI and adipocyte size and that adipose 
tissue macrophages are the primary source of pro-inflammatory adipokines. 
Inflamed adipose tissues, especially visceral and subcutaneous, increase their pro-
inflammatory adipokine secretion. These adipokines then leak into the circulation and 
potentially alter the microvasculature, various organs, and tissues. Free fatty acids are 
released from adipose tissue during this inflammatory response. These free fatty acids 
lead to intracellular accumulation of triglycerides, the development of more ectopic fat 
(fat that surrounds the organs), and lipid-derived metabolites, exacerbating the 
inflammatory response (Unger 2002). This imbalanced adipokine production, especially 
the increased secretion of pro-inflammatory adipokines, is observed in metabolic 
conditions such as obesity, insulin resistance, and T2DM (Romacho et al., 2014).  
Tumor necrosis factor-alpha (TNF-α), an adipokine involved in systemic 
inflammation and regulation of immune cells, has been identified as a pro-inflammatory 
adipokine important to the development of insulin resistance and obesity. Early research 
found that TNF-α was highly expressed in obese and diabetic rodents and that there was a 
correlation between the expression of TNF-α and peripheral insulin resistance 
(Hotamisligil & Spiegelman, 1993). Translating these findings from rodents to humans, a 
follow up study conducted by Hotamisligil et al. (1995), showed that in 19 obese 
premenopausal women there was a 2.5 fold increase in TNF-α mRNA expression in 
subcutaneous adipose tissue compared to their lean counterparts. They also reported a 
positive correlation established between the TNF-α mRNA expression levels in the 
adipose tissue and the level of hyperinsulinemia (an indirect measure of insulin 
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resistance). Additionally, obese females were studied before and after a weight loss 
intervention targeting a 17% reduction in BMI. These patients exhibited an improvement 
in insulin sensitivity and a reduction in TNF-α mRNA expression in adipose tissue. This 
study suggests that abnormal cytokine and adipokine production in adipose tissue plays a 
role in the pathogenesis of obesity-induced insulin resistance (Hotamisligil et al., 1995) 
and that it may be reversible. 
2.1.4 Myocardial Fat, Lipotoxicity, and Inflammation in the Heart 
 Although cardiometabolic syndrome is associated with peripheral fat deposition 
and inflammation, it is also associated with adipose accumulation in and around the heart 
as epicardial adipose tissue (EAT) and intra-myocardial fat. This fat deposition localized 
to the heart likely has a direct effect on cardiac function and may be a major contributing 
factor to the high prevalence of heart disease in patients with diabetes and obesity. 
  In a study by Iacobellis et al. (2003), the researchers were interested in estimating 
the volume of epicardial adipose tissue relative to anthropometric, metabolic, and cardiac 
parameters of cardiometabolic syndrome using echocardiography. Seventy-two subjects 
(36 males and 36 females) were recruited with BMIs ranging from 22 to 42 (median 34). 
The subjects were identified as exhibiting cardiometoblic syndrome based on how many 
risks factors were present. The researchers found that subjects with predominant visceral 
fat accumulation and at least two clinical and metabolic parameters of metabolic 
syndrome, showed higher epicardial adipose tissue compared to individuals with 
predominant peripheral fat distribution and no clinical parameters. In addition, data 
showed that EAT had a strong positive correlation with BMI, waist circumference, 
diastolic blood pressure, fasting plasma insulin, LDL cholesterol and plasma adiponectin. 
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It was further suggested that individuals exhibiting impaired insulin sensitivity, 
independent of BMI, showed the highest epicardial adipose tissue thickness (Iacobellis et 
al., 2003). In all, this study positioned cardiac fat as a new cardiovascular risk factor 
since it is associated with increased insulin resistance, visceral fat and, in general, with 
the metabolic syndrome. 
  However, the location of cardiac fat may play a pivotal role in its relationship 
with obesity, T2DM, cardiometabolic syndrome, and inflammation. EAT comprises 
approximately 30% of the intrathoracic fat while the majority is present as extra-
pericardial fat (PAT); (Sironi et al., 2011). EAT is concentrated in the atrioventricular 
and interventricular grooves and along the branches of the coronary artery. EAT is close 
to the myocardium and has no real physical barrier to the coronary arteries. PAT is EAT 
that is located in these areas along with paracardial fat. Paracardial fat is situated on the 
external surface of the parietal pericardium within the mediastinum (Williams, 1995; 
Iacobellis et al., 2005; Wheeler et al., 2005; Sironi et al., 2004). This is important since 
the amount of fat that can be deposited into the EAT sac is extremely limited, thus, the 
majority of fat begins to accumulate in the PAT (Sironi et al., 2012). This has led some 
researchers to consider PAT as being more vital in cardiovascular risk management 
compared to EAT. 
A study conducted by Sironi et al. (2012), using magnetic resonance imaging 
(MRI), tested whether EAT or extra-pericardial fat had similar clinical relevance using a 
large number of subjects, including patients with T2DM. One hundred thirteen 
individuals were recruited (94 men and 19 women) with a mean age of 52 and BMI 
ranging from 18 to 40 and 21 had T2DM. The authors looked at all four fat depots: 
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visceral, subcutaneous, epicardial, and extra-pericardial fat. The authors found that all fat 
depots increased in proportion to the degree of obesity. EAT and PAT were significantly 
correlated with BMI. Visceral fat and PAT were inversely correlated with insulin 
sensitivity but not with EAT. In addition, when relating fat depots to CVD risk and 
cardiometabolic risk, visceral, PAT, and intrathoracic fat were significantly associated 
with three or more cardiometabolic risk factors compared to subcutaneous or EAT. 
Further, in a stepwise multiple regression model adjusting for gender and BMI, blood 
pressure was only significantly associated with PAT only while insulin resistance and 
triglyceride concentrations were best associated both with PAT and visceral fat but not 
EAT (Sironi et al., 2012). The authors concluded that visceral fat was the best marker for 
altered CVD risk profile while increased PAT was associated with coronary heart disease 
risk. 
PAT has also been shown to have a high capacity for non-esterified free fatty acid 
release and is proposed to be a preferred metabolite source for the myocardium 
(Marchington et al., 1989). With the close proximity to the myocardium and the changes, 
especially the inflammatory response, that occur with obesity and T2DM, the PAT and 
EAT exhibit the same inflammatory changes as observed in visceral adipose tissue. 
Indeed, Baker et al. investigated the expression profile of EAT from human EAT of 
patients suffering from coronary artery disease. Some of these patients (n=10) exhibited 
T2DM but were untreated while also gathering omental, abdominal subcutaneous, thigh 
adipose tissues from individuals with no T2DM and CAD. Using PCR and gene 
expression assays, Baker et al. (2006) established from their results that EAT exhibits 
metabolic risk markers and pro-inflammatory agents, such as TNF-α, IL-6, plasminogen 
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activator inhibitor-1 (PAI-1), were similar to omental adipose tissue (visceral) in that of 
non-CAD patients. The authors proposed that this pro-inflammatory profile of EAT and 
its close proximity to the myocardium may have direct influence on myocardial 
metabolism, cardiac dysfunction, lipid accumulation, and macrophage infiltration that 
leads to more inflammation (Baker et al., 2006). 
The heart is not a major site for lipid storage but fatty acids in the form of 
triacylglycerols and phospholipids can be easily stored within the cardiomyocytes. This is 
evident in disease states as cardiometabolic syndrome where circulating fatty acids are 
high (Gastaldelli et al., 2012). The accumulation of these lipids deposits changes cardiac 
metabolism. Normally, the mammalian heart is able to obtain its energy from a balance of 
fatty acid and carbohydrate oxidation. Under the conditions of inflammation, lipid 
accumulation and insulin resistance, the heart begins to lose the ability to oxidize 
carbohydrates and then relies on fatty acids. This in turn causes the heart to rely on β-
oxidation, then glucose oxidation is downregulated and this leads to the production of 
damaging intermediates such as reactive oxygen species (ROS), ceramides, and 
diacylglycerols that advance cardiac insulin resistance and promotes lipotoxicity (Kok et 
al., 2012; Lewin et al., 2008).  Lipotoxicity is defined as the alteration to the intracellular 
signaling within metabolic tissues due to lipids and lipid utilization (Wende et al., 2012). 
Lipotoxic cardiomyopathy is a disorder of the myocardium induced by the damaging 
effects of free fatty acids and inflammation and is characterized by mitochondrial 
dysfunction, cardiomyocyte apoptosis, and contractile dysfunction. Further, lipotoxicity 
influences sarcoplasmic reticular Ca2+ stores to propagate contractile dysfunction while 
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increasing oxygen demand in the heart, exacerbating myocardial damage (Turer et al., 
2012).  
This lipotoxic heart has been witnessed in individuals diagnosed with T2DM. 
Indeed, an autopsy study conducted by Nakanishi & Kato (2014) investigating fatty 
hearts and changes in adipose triglyceride lipase of seventy-three hearts found that 
patients with diabetes mellitus were more likely to exhibit fatty hearts. These seventy-
three hearts were randomly collected and tissues were sectioned from the anteroseptal 
area or from a different part of the left ventricle if any tissues scars were present. The 
tissue sections were subjected to immunohistochemical staining and tissue lipid content 
was extracted. The authors found that seven out of seventy-three hearts were fatty hearts. 
These seven hearts were identified as positive for lipid deposition and these individuals 
were clinically diagnosed with T2DM. Compared to the non-lipid deposited hearts, 
patients with these fatty hearts had significantly higher incidences of myocardial 
infarctions and heart failure. In addition, the fatty hearts from the diabetic cases exhibited 
significantly elevated triglyceride content in the myocardium compared to non-T2DM 
cases. Interestingly, the adipose triglyceride lipases were intact and no changes were 
noted in all cases. It can be postulated that these changes in the myocardium were not due 
to over-activation or changes to adipose triglyceride lipases, thus, it is possible that 
diabetes is associated with myocardial lipid accumulation and inflammation may play a 
role in this accumulation process. 
The authors of this study found the hearts of patients from the diabetes cases 
experienced more severe histological damage than non-diabetes mellitus cases. Due to 
this higher incident, it appears that individuals with T2DM are more susceptible to 
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cardiomyopathies. Further, the authors believe that this histological damage may not be 
due to lipid deposition alone, but may be correlated more with the factors secreted from 
epicardial adipose tissue. Indeed, individuals with T2DM have increased EAT depots and 
the factors released from the EAT are associated with the development of cardiomyocytes 
dysfunction. EAT is known to be metabolically active and produces adipokines such as 
TNF-α, IL-1, adiponectin, IL-6, and free fatty acids (Mazurek et al., 2003). Thus, an 
interaction between lipid accumulation, epicardial adipose tissue, and secreted factors 
likely plays a role in the development of cardiomyopathies and cardiac dysfunction in 
diabetic cases, though the role of inflammation in early stages of the disease progression 
needs further investigation. 
2.1.5 Role of NF-κB 
Inflammation is defined as a series of cellular and humoral reactions meant to 
defend the body from various insults such as infections or tissue damage. The ultimate 
goal of inflammation is to restore the function and morphological integrity of the affected 
tissues (Lee & Lee 2014; Cildir et al., 2013). Nuclear factor kappa B (NF-κB) represents 
one of the many key systems that mediate both neurohormonal and pro-inflammatory 
signals, especially in hypertrophy and fibrosis of the heart (Pechanova & Simko, 2010). 
NF-κB initiates the coordinated expression of inflammatory responses in the 
myocardium, which includes the increased expression of pro-inflammatory cytokines, 
chemokines, and cell adhesion molecules (Hernadez-Presa et al., 1997; Luft, 2001; 
Sekiguchi et al., 2004). This pathway is not only responsible for inducing a pro-
inflammatory response but it also can exhibit protective responses. 
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 In mammals, the NF-κB super family of transcriptional factors consist of at least 
five genes that encode the members RelA (p65), RelB, c-Rel, p50, and p52 (Hayden & 
Ghosh, 2008). All of these members are conserved throughout evolution and share a Rel 
homology domain (RHD), allowing DNA binding and dimerization between members. 
Transcription by NF-κB only works when two members form a heterodimer. In the heart 
the most predominant heterodimer is p50/p65 complex. With all transcription factors, 
nuclear localization is necessary for down-stream gene transcription. Indeed, if no signals 
are active, NF-κB exists as an inactive dimer in the cytoplasm of cells bound to its 
inhibitor (IκB) proteins (IκBα,-β,-ε) (Gordon et al., 2011).  
 To induce activation of NF-κB, phosphorylation-dependent degradation of IκB 
proteins via a proteasomal regulated pathway must occur. This phosphorylation is a key 
step in NF-κB activation and is mediated by IκB-kinase (IKK). Liberating NF-κB from 
its inhibitory complex causes NF-κB to become active and translocate to the nucleus, 
where it begins to bind to the promoters or enhancer regions of target genes containing a 
consensus motif 5’-GGGRNWYYCC-3’ (R=any purine, N=any nucleotide, W=adenine 
or thymidine, Y=any pyrimidine) and commencing transcription (Gordon et al., 2011; 
Pechanova & Smiko, 2010). Indeed, NF-κB transcription and activation has been found 
in various models of cardiac hypertrophy, hypertension, myocardial ischemia, and 
cardiac remodeling (Pechanova & Smiko, 2010; Kupatt et al., 1999). 
 Li et al. (2004) was one of the first groups to show that NF-κB activation is 
required for the development of pathological cardiac hypertrophy in vivo. The researchers 
used male Sprague-Dawley rats and separated them into two groups: an aortic band group 
to elicit hypertrophy and a sham operated group (n=8 -10 in each group). The aortic band 
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group had binding of the ascending aorta with silk sutures while the sham group had 
small incisions made to mimic the surgery but no actual banding occurred. In a similar 
group, the researchers used transfection of an IκBα dominant negative mutant super 
repressor of NF-κB activation and PDTC, an antioxidant that has been shown to inhibit 
NF-κB activation, to determine if these interventions can attenuate hypertrophy in these 
animals. First, aortic binding lead to hypertrophy in the hearts of the aortic band group 
compared to the age-related sham group. To verify, real time PCR was used to examine 
gene expression of two genes related to cardiac hypertrophy, ANP (atrial natriuretic 
peptide) and BNP (brain natriuretic peptide). ANP and BNP mRNA gene expression 
levels were increased in the aortic band group compared to the sham, showing that 
cardiac hypertrophy did occur. Using electrophoretic mobility shift assays (EMSA), they 
found increased NF-κB binding activity in hypertrophied hearts. Along with the increase 
in NF-κB binding activity, IKKβ activity was also increased. In addition, using their 
transfection of IκBα and PDTC, they found that they could attenuate the development of 
cardiac hypertrophy in vivo. This study demonstrated that NF-κB activation is required 
for the development of cardiac hypertrophy and that inhibiting NF-κB attenuates this 
detrimental hypertrophy. Interestingly, the researchers stated that ANP & BNP gene 
expression requires NF-κB activation and that the increased expression was 
representative of cardiac hypertrophy (Li et al., 2004; Liang & Gardner, 2001; Purcell et 
al., 2001). However, in conditions such as obesity and diabetes, inflammation may play a 
role in the activation of NF-κB in the heart.  
 Inflammation and microbial products can also activate NF-κB. Pro-inflammatory 
markers such as TNF-α or IL-1β can activate NF-κB through what is considered to be the 
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“canonical pathway”.  In this pathway, the IKK dimer that consists of IKKα and IKKβ 
are activated by TNFR (TNF-α) receptor 1, interleukin-1 receptors (IL-1R) and other pro-
inflammatory cytokine receptors. The binding at these locations causes the recruitment of 
signal adaptors like myeloid differentiation primary response gene 88 (MyD88) that 
result in the activation of tumor necrosis factor receptor-associated factor (TRAF6). 
TRAF6 allows for auto-ubiquitination to occur which, in turn, allows for the recruitment 
of other intermediates that phosphorylate IKK. Indeed, TRAF6 along with receptor 
interacting protein (RIP) help create a scaffold for binding of pro-inflammatory kinases 
TAK1 that phosphorylate IKK (Van der Heiden et al., 2010). Majority of the literature 
that focuses on the non-canonical pathway has been on lymphocytes and information on 
other cell types is limited. Thus we will mainly focus on the canonical pathway. 
 In a recent study by Thomas et al. (2014), the 3M mouse was used to study the 
protective effects that NF-κB suppression would have in diabetes-induced cardiac 
dysfunction. The 3M animal model is a cardiac-specific transgenic mouse model that 
overexpresses IκBα with a triple mutation that prevents its phosphorylation, thus 
suppressing the canonical NF-κB pathway. The authors used C57B1/6J wild type mice as 
a control group and another group of these same mice as diabetic models. 3M mice and 
some of the wild-type C57B1/6J mice were given streptozotocin (STZ) to induce diabetes 
while animals in the control groups were given a placebo vehicle. Animals underwent 
echocardiography to determine cardiac function and after 24 weeks were sacrificed and 
heart tissues extracted. Western blots and real-time PCR were conducted using RNA 
extracted from heart tissues. The researchers found that in the hearts of the diabetic wild-
type mice, through DHE staining, an increase in oxidative stress compared to the 3M 
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diabetic and control group was witnessed. The 3M control mice initially exhibited 
oxidative stress but greater levels were observed in the wild-type diabetic mice after 24 
weeks. Molecular markers such as β-myosin heavy chain (β-MHC), ANP, and BNP were 
increased in wild-type diabetic mice and not in the 3M diabetic mice. As stated 
previously, ANP and BNP need NF-κB activation to increase their expression. Lastly, 
compared to wild-type diabetic mice, the 3M diabetic mice lacked an increase in the p65 
subunit of NF-κB in the nuclei, which correlated with decreased NF-κB activity in these 
mice. 
 The 3M mouse mutation is cardiac-specific. Thomas et al. (2014) observed that 
lack of NF-κB activation protects animals from developing diabetic cardiomyopathy. 
Canonical NF-κB activation in the diabetic myocardium is required for cardiac 
remodeling. As evidenced by their results, genetic silencing of NF-κB, specifically in the 
heart, helps prevent diabetic cardiomyopathies. In addition, the levels in plasma and 
expression in tissues of pro-inflammatory cytokines have been shown to change with 
time in T1DM and T2DM but the authors observed no increase in expression of 
inflammatory cytokines such as IL-1β, IL-6, or TNF-α. This is supported by studies in 
streptozotocin treated rats.  
 Other stimuli can affect the canonical NF-κB pathway. Hypoxia, ROS, and 
mechanical stretch are known to be effective activators of the canonical pathway. Indeed, 
in conditions like diabetes and obesity, where states of inflammation are chronic, NF-κB 
may be overly stimulated (Arkan et al., 2005; Bierhaus et al., 2001). This overt 
stimulation promotes more NF-κB transcription of inflammatory markers.  Some of these 
pro-inflammatory markers such as matrix metalloproteinases, TNF-α, IL-1β, and MCP-1 
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that are active during cardiomyopathy are regulated by NF-κB (Van der Heiden et al., 
2010).  
 In conclusion, the NF-κB family controls multiple processes, including immunity, 
inflammation, cell survival, differentiation, and proliferation. Pro-inflammatory 
cytokines, reactive oxygen species, and microbial products can induce NF-κB signaling, 
resulting in transcriptional regulation of pro-inflammatory genes such as TNF-α, IL-8, 
IL-1β, MCP-1, and many more, which promote the inflammatory process. Indeed, 
diabetes and obesity are both conditions with chronic subclinical inflammation that 
affects NF-κB. Individuals suffering from diabetes and obesity are more likely to exhibit 
over-activation of NF-κB. NF-κB has been shown to play a role in the development of 
cardiac hypertrophy and cardiac dysfunction in these individuals. However, there 
currently exists little data on the effects of NF-κB in the earlier stages of disease 
(overweight and insulin resistance) in the heart and whether interventions such as 
exercise or caloric restriction can alter or prevent pathology. 
2.1.6 Detection of Molecular Pathology in the Heart 
When pathophysiological stresses are introduced in the heart, certain genes are 
activated as a way to compensate and remodeling of the heart occurs.  A well-
characterized adaptation of the heart to stress is the fetal gene program or the activation 
of genes that are expressed during early fetal circulation but become silent as the 
mammalian heart ages. The expression of genes in this group play an important role in 
cardiovascular diseases such as cardiac hypertrophy (Kuwahara et al., 2012; Bernado et 
al., 2010) and may be useful in characterizing cardiac dysfunction due to obesity and 
diabetes or insulin resistance. The genes involved in this program are: atrial and brain 
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natriuretic peptide (ANP and BNP, respectively), fetal isoforms of contractile proteins 
(skeletal α-actin and α-, β-myosin heavy chain), fetal-type cardiac ion channels 
(SERCA2a), and smooth muscle genes (smooth muscle α-actin); (Kuwahara et al., 2012; 
Bernado et al., 2010).   
ANP & BNP are peptide hormones that are encoded by the Nppa and Nppb genes, 
respectively. These hormones are secreted in the adult heart in response to cardiac wall 
stretch and strain (Dietz, 2005). ANP is released by atrial cardiomyocytes while BNP is 
released from ventricular cardiomyocytes. Both hormones respond to high blood pressure 
(cardiac wall stretch and strain) and act to reduce water, sodium, and adipose loads to 
induce a decrease in blood pressure. However, both ANP and BNP have been discovered 
to antagonize cardiac hypertrophy, fibrosis, and to stimulate lipolysis (breakdown of 
lipids into fatty acids/triglycerides); (Cox et al., 2014; Rosenkranz et al., 2003; Franco et 
al., 2004; Wang et al., 2003). 
The sarcoplasmic reticulum Ca2+ ATPase 2 (Serca2a) is another important 
member for the fetal gene program. Serca2a is responsible for the re-uptake of calcium 
into the sarcoplasmic reticulum following the contraction of the sarcomere, allowing 
muscular relaxation. Serca2a expression levels are maintained through adulthood but a 
decrease is observed in the diabetic heart and may play a role in the diastolic dysfunction 
that leads to diabetic cardiomyopathy (Cox et al., 2014). 
The myofilament proteins α-myosin heavy chain (α-MHC) and β-myosin heavy 
chain (β-MHC) exhibit different properties and their ratio is changed during cardiac 
hypertrophy. α-MHC, which has the highest ATPase activity and contractile velocity, is 
highly-expressed during adulthood while β-MHC, which has the lowest ATPase activity 
23 
 
and lowest contractile velocity, is highly-expressed during fetal development. A ratio 
between α-MHC and β-MHC exists which is maintained in adulthood. However, during 
cardiac hypertrophy, the ratio decreases. It is important to note that humans exhibit more 
β-MHC than α-MHC. Rodents exhibit the α-MHC/β-MHC ratio as described previously 
(Gustafon et al., 1987; Lyons et al., 1990; Reiser et al., 2001; Miyata et al., 2000). In 
addition to the myosin cytoskeletal proteins, skeletal α-actin changes in the hypertrophied 
heart. Skeletal α-actin is highly-expressed in the fetal heart and is replaced by cardiac α-
actin in adulthood. During cardiac hypertrophy and cardiac dysfunction, there is a re-
expression of and conversion to skeletal α-actin (Driesen et al., 2009; Ren et al., 2012). 
Some evidence suggests that the fetal gene program is activated in diabetes.  In a 
study conducted by Depre et al. (2000), Wistar rats were injected with β-cell toxin 
streptozotocin (STZ) to induce T2DM while another group of Wistar rats was injected 
with vehicle only to serve as a control group. The animals were then sacrificed and RNA 
was extracted from the animals’ heart tissue. The authors used polymerase chain reaction 
(PCR), to assess the gene expression of a myriad of contractile proteins and ion pumps. 
The researchers found that the gene expression of many of the contractile proteins and 
ion pumps (e.g. SERCA2a, β-/-α MHC) were decreased in the diabetic hearts and 
exhibited the same gene expression as what is observed in the hypertrophied heart. 
In addition to the fetal gene program, cardiac pathology related to diabetes and 
obesity may be evident as fibrosis.  Yagi et al. (1997), characterized the changes in the 
myocardium of the Otsuka Long-Evans Tokushima Fatty rat (OLETF), a genetic animal 
model of mild obesity and non-insulin dependent T2DM, evaluating fetal gene expression 
and genes involved in cardiac fibrosis as markers for changes in cardiac performance. In 
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this study, the Long-Evans Tokushima-Otsuka (LETO) rats were used as a genetic 
control for the OLETF rats. LETO rats are lean rats and are from the same colony that the 
OLETF come from, thus having the same genetic background. The hearts of animals 
were characterized at week 14 (a pre-diabetic state), week 30 (non-insulin dependent 
diabetes mellitus phase), and week 54 (insulin dependent diabetes mellitus phase) by left 
ventricle mRNA expression. The researchers found that although there were no 
differences between fetal gene expression program markers at 14 weeks, at 30 weeks, 
OLETF left ventricle expression of β-MHC was greater than LETO.  mRNA levels for 
contractile proteins α-/β-MHC and ANP, and were significantly different between groups 
at 54 weeks.  Specifically, α-MHC mRNA levels were lower and ANP mRNA levels 
were 1.3-fold higher in the OLETF rat compared to the LETO at 54 weeks.  This data 
indicates that β-MHC expression differences appear early in the progression of the 
OLETF disease phenotype whereas other fetal gene program indicators of dysfunction do 
not appear until later in this model.  
There is evidence that cardiac fibrosis occurs at early time points in the OLETF 
model and that it may be related to inflammation.  Yagi et al. (1997), reported that at 14 
weeks of age, the left ventricular gene expression of collagen types I, III and IV, along 
with laminin, were significantly enhanced in OLETF compared with LETO rats of the 
same age. Collagen types III and IV and laminin mRNA levels remained elevated in 
OLETF rats at week 30 compared to LETO. Transforming Growth Factor-β (TGF-β) is a 
pleiotropic cytokine that can regulate fibrogenesis and is released from pro-inflammatory 
cells (e.g. macrophages). The authors showed that mRNA levels of 14-, 30-, and 54-
week-old OLETF rats were 1.5-, 1.6-, and 1.3-fold greater, respectively, than in the 
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LETO rats examined at those same time points. Thus, markers of fibrosis are evident at 
early stages in the OLETF model when animals are overweight and insulin resistant. 
Importantly, although OLETF rats develop hypertension, authors reported no 
alterations in cardiac TGF-β or β-MHC in genetically hypertensive rats (SHR) suggesting 
different regulation of cardiac pathology between hypertension and diabetes/obesity 
(Yagi et al., 1997).  The involvement of TGF-β in cardiac fibrosis in this pre-diabetic 
stage is still unclear. Inflammation may play a role in linking TGF-β and cardiac fibrosis 
in the OLETF rat.  Exploring cardiac fibrosis gene expression in young OLETF rats and 
its interaction with inflammation may provide further insight into the genetic and 
molecular pathways that may exacerbate the risk of CVD in obese and diabetic 
individuals. 
2.2 Role of Exercise and Caloric Restriction 
2.2.1 Exercise 
 Exercise is well-known to be a powerful treatment for obesity-related metabolic 
complications, including insulin resistance, hypertension, impaired glucose tolerance or 
diabetes, hyperinsulinemia, and dyslipidemia that are characterized by elevated adipose 
accumulation (Kim et al., 2008; Hu et al., 2001; Tuomilehto et al., 2001). A study by Hu 
et al. (2001), that followed approximately 85,000 female nurses for 16 years, found that 
adopting a healthy diet and physical activity reduced obesity, risks for cardiovascular 
disease, and chances of developing cancer and other chronic diseases.  In addition, 
physical activity improves glucose homeostasis and insulin sensitivity, coronary blood 
flow and cardiac function, enhances endothelial function, and reduces blood pressure 
26 
 
(Murphy et al., 2009). These improvements in cardiac function may be related to a 
reduction in overall fat mass and pro-inflammatory state, systemically and at the level of 
the myocardium.  However, understanding the independent effect of exercise from 
weight or fat loss is difficult given that many studies do not control fat loss. 
 Trachta et al. (2014) investigated the effects of regular physical activity on 
improving systemic sub-clinical inflammation and other obesity-related pathologies 
through the modulation of inflammatory profile of adipose tissue. Fifteen non-diabetic 
obese females with arterial hypertension were recruited for the study and were placed in a 
three-month aerobic exercise program consisting of 30 minutes of aerobic exercise for 
three times a week. Fifteen healthy lean women that were free of any cardiovascular and 
metabolic parameters were selected to serve as a control group. Subcutaneous adipose 
tissue samples were collected from the abdominal region and RNA was extracted and 
used in PCR to examine pro-inflammatory gene expression. After their intervention, 
Trachta et al. (2014) found that regular aerobic exercise significantly decreased body 
weight and body fat, systemic sub-clinical inflammation, and insulin resistance. Though 
the exercise intervention did not have much effect on the endocrine function, there was 
an improvement in the pro-inflammatory gene expression such as chemokine C-C motifs 
2, 3, 4, IL-1β, IL-6, for example, in subcutaneous adipose tissue. The obese non-diabetic 
women exhibited a decrease in a myriad of pro-inflammatory cytokines though not 
statistically significant. In addition, the authors noted that though the subcutaneous 
adipose tissue is the largest of the fat depots, it is not a major player in systemic 
inflammation compared to visceral adipose tissue. Since the non-diabetic obese 
participants had a reduction in waist circumference, it can be postulated that the reduction 
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in visceral adipose tissue due to aerobic exercise lead to improvements in systemic 
inflammation.  
Longitudinal studies have shown that daily physical activity helps combat 
inflammation by reducing adiposity and thus diminishing the macrophage infiltration. In 
studies that looked at 12-week interventions of sedentary males with metabolic 
syndrome, they found that moderate-intensity exercise reduced inflammatory markers 
such as MCP-1 and IL-8. Similar results in other studies investigating individuals with 
heart failure found a reduction in pro-inflammatory markers and an increase in anti-
inflammatory proteins (Goldhammer et al., 2005).  Markers such as IL-1, MCP-1, and C-
reactive protein (CRP), which is released from the liver, were all significantly reduced 
compared to levels in individuals who did not exercise. Importantly, these benefits were 
evident even in the absence of significant weight loss (Goldhammer et al., 2005). In 
addition, exercise is able to attenuate insulin resistance and improve insulin sensitivity in 
many different tissues, including the heart. Thus, exercise can be an effective treatment 
for obesity and T2DM, especially if they both exist concomitantly (Dalzill et al., 2014). 
Kim et al. (2008) conducted a study to determine whether three-months of aerobic 
exercise training without caloric restriction (by having the participants maintain a food 
log and normal eating habits) produced changes in EAT and its relation to abdominal 
visceral adipose tissue changes. Twenty-four obese middle age Japanese males were 
recruited. The participants were supervised by an exercise physiologist for compliance 
and aerobic exercise intensity was based on the individual’s maximal heart rate attained 
from an initial aerobic fitness test. The researchers found that EAT thickness (measured 
by echocardiography) was reduced in obese men after a three month aerobic exercise 
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intervention, compared to pre-intervention. Interestingly, the percent change in EAT was 
twice as high compared to changes in waist, BMI, and visceral adipose tissue. In addition, 
the reduction in EAT was accompanied by a reduction in the visceral adipose tissues. 
Some participants in this study exhibited the cardiometabolic syndrome according to the 
Japan Society for the Study of Obesity criteria and exhibited improvement in insulin 
sensitivity and fat reduction both in visceral and epicardial adipose tissue. This study was 
the first study to show that exercise has a potent effect in reducing EAT thickness and 
improving biological markers associated with obesity and cardiometabolic syndrome.  
Kim et al. (2008) published one of the first studies investigating the effects of 
exercise on the heart, especially on EAT, and it did not include caloric restriction as part 
of their intervention. Many studies use a combination of exercise and calorie restriction in 
their interventions and the outcomes that are presented cannot be attributed either to 
exercise or caloric restriction alone. Many agree that weight loss improves many of the 
outcomes in obesity and diabetes. The mechanisms behind the direct effects of exercise 
on the heart and other tissues are still heavily investigated areas. In all, exercise may 
prove to be an effective intervention for improving inflammation and cardiac dysfunction 
in individuals with cardiometabolic syndrome. 
2.2.2 Caloric Restriction 
 Caloric restriction (CR) is classified as a state in which the energy intake of an 
individual or animal is minimized to low-normal levels while maintaining a balance of 
macronutrients like protein and carbohydrates. CR usually consists of about 30-50% 
reduction in energy intake that is required to maintain normal body weight and adiposity, 
leading to a leaner phenotype. In animal studies, it is usually administered early in the 
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animal’s life so that there is no weight loss and the changes are attributed to the condition 
of CR and not weight loss. In humans, it is administered in adulthood, where the results 
can be contributed to weight loss or the caloric restriction itself. Therefore, in humans, 
determination of the independent effects of CR versus weight loss is difficult (Weiss & 
Fontana, 2011). 
 With respect to the heart, CR may prove to be an effective intervention for 
individuals who are obese and/or diabetic. Hammer et al. (2008) studied the effects of 
prolonged caloric restriction in 12 obese patients with T2DM on myocardial triglyceride 
content and cardiac function. The intervention lasted for 16 weeks and the participants 
had their myocardial triglyceride content and left ventricle function measured through 
photon magnetic resonance spectroscopy. The authors found that the caloric restriction 
had reduced the BMI of the patients and improved many of their metabolic parameters. 
Indeed, the participants had improved glycemic control (decreases in fasting plasma 
glucose levels), and hemoglobin A1c levels, plasma non-esterified fatty acids, and liver 
enzymes such as CRP (inflammatory biomarker), were all reduced after prolonged caloric 
restriction. In addition, myocardial triglyceride content and left ventricular mass 
decreased while improving cardiac output and both systolic and diastolic blood pressure. 
 The effects of caloric restriction on EAT were further supported by the work of 
Iacobellis et al. (2008). In this study, 20 severely obese subjects (BMI≥40 kg/m2) 
underwent a very low calorie (900 calories) diet weight loss program for 12 weeks. 
Anthropometric measures were taken and epicardial adipose tissue was measured using 
echocardiograms. Iacobellis et al. found that severely obese subjects had significantly 
higher epicardial fat thickness compared to lean subjects. After the intervention, the 
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subjects decreased their body weight and BMI by approximately 20%, had a 23% 
reduction in their waist, and a 32% reduction in epicardial fat thickness. In addition, left 
ventricular mass (LVM) was significantly reduced and improvements in diastolic 
function were witnessed. These changes all correlated strongly with the decrease in 
epicardial fat thickness. Thus caloric restriction, even for a short period, can elicit 
powerful changes and improvements in the myocardium, especially in severely obese 
individuals.  
 Though there may be some differences in administration of CR, evidence shows 
that in animals and humans, CR is able to increase longevity and reduce death due to 
chronic diseases such as cancer, T2DM, obesity, and cardiovascular disease.  Indeed, 
research has shown that CR is able to attenuate the production of ROS and oxidative 
damage by activation of SIRT1 and transcription factor NF-E2-related factor (Nrf2). In 
addition, CR is able to attenuate age-related vascular inflammation by improving the NF-
κB inhibition of pro-inflammatory gene transcription, thereby causing NF-κB to become 
active in anti-inflammatory gene transcription and reducing a pro-inflammatory state. 
Lastly, like exercise, CR is able to reduce adiposity and inflammatory markers, especially 
in the cardiovascular system, leading to healthy cardiovascular function and can even 
decrease the adverse effects of cardiomyopathy (Weiss & Fontana, 2011; Kemi et al., 
2000).  
2.2.3 Comparative Effectiveness of Exercise and Caloric Restriction 
Comparative effectiveness studies are novel ways to inform health-care decisions 
by providing evidence of the effectiveness, benefits, and/or detriments of different 
treatment options. Few studies have looked at comparative effectiveness of exercise or 
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caloric restriction on pathologies of the heart, especially in early overweight and insulin 
resistance. Both exercise and caloric restriction are beneficial for improving 
cardiovascular health in individuals who suffer from cardiometabolic syndrome, 
however, no studies have been conducted to determine which is more beneficial. 
A report by Crissey et al. (2014) is one of the few that has compared exercise to 
caloric restriction for changes related to cardiometabolic syndrome. The researchers used 
OLETF rats to study the changes in the various adipose tissue depots either through 
exercise or caloric restriction in relation to vascular insulin resistance and inflammation. 
The study was conducted using 30 male OLETF rats that were purchased and randomized 
into 3 groups: sedentary (SED), caloric restriction (CR), and exercise (wheel running; 
WR). The animals in the caloric restriction were fed 70% ad libitum, exhibiting a modest 
30% caloric reduction. The OLETF rats were placed in each intervention for 8 weeks and 
then sacrificed at 20 weeks, at which time the animals present with an early insulin 
resistant and overweight phenotype. Perivascular adipose tissue from the thoracic aorta, 
retroperitoneal white adipose tissue, inguinal subcutaneous adipose tissue and brown 
interscapular adipose tissue were excised from the animals. A portion of the perivascular 
adipose tissue was used for in vitro assessment of cytokine secretion. RNA was extracted 
from the various adipose tissues and aortic samples. Real-Time PCR was used to 
determine gene expression. 
The researchers found that the exercise (wheel running; WR) and caloric 
restriction (CR) groups had improved body composition, exhibiting lower body fat 
percentages and less visceral adipose tissue mass compared to the sedentary group. Both 
exercise and caloric restriction groups had improved fasting total cholesterol, LDL 
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cholesterol, leptin, glucose, non-esterified fatty acids (NEFA), and triglycerides (Table 
4). In addition, the exercise group exhibited improvements in HOMA-IR, lower plasma 
insulin, and lower circulating MCP-1. In the retroperitoneal adipose tissue, both WR and 
CR groups had lower expression of leptin, MCP-1, TNF-α, IL-6, PAI-1, and intercellular 
adhesion molecule-1 (ICAM-1) compared to SED. Expression of these inflammatory 
markers were higher in brown adipose tissue, in the WR group only. In the periaortic 
adipose tissue, both CR and WR exhibited lower expression of leptin, MCP-1, TNF-α, 
with the WR group exhibiting a lower PAI-1 expression compared with the SED group. 
In the CR group, the periaortic fat exhibited lower IL-6, E-selectin, and ICAM 
expression. Subcutaneous adipose tissue had lower leptin and MCP-1 expression. Insulin-
stimulated aortic relaxation was significantly greater in WR rats relative to SED and CR 
rats (Crissey et al., 2014). 
In addition, Crissey at al. (2014) investigated gene expression indicative of 
immune cell infiltration into peripheral adipose tissue depots, periaortic adipose, and 
aorta to determine if WR or CR was able to attenuate their expression. Markers for 
immune cell infiltration, such as cluster of differentiation 4 (CD4), cluster of 
differentiation 8 (CD8), and EGF-like module containing mucin-like hormone receptor-
like 1 (F4/80), revealed that WR and CR reduced expression of these three markers in the 
aorta and retroperitoneal adipose tissue compared with the SED group. Interestingly, WR 
and CR both reduced leptin, IL-6 and MCP-1 secretion from periaortic adipose tissue 
indicating that immune cells and cytokine release from adipose may contribute to tissue 
inflammation in OLETF rats.  CD4 and CD8 are markers commonly expressed in 
macrophages, monocytes, and T-cells while F4/80 is another macrophage glycoprotein 
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receptor that is expressed in high levels in various macrophages and more importantly 
can be expressed in macrophages of connective tissue such as the heart (Heidt et al., 
2014; Weisberg et al., 2003). EX and CR were able to attenuate their expression in 
adipose tissue and may be able to induce similar changes in the immune cell infiltration 
within myocardial tissue. 
Overall, these results show the improvements on adipose tissue and inflammation 
that can occur either with exercise or caloric restriction. Both can reduce the 
inflammatory markers that are detrimental in obesity and insulin resistance that lead to 
cardiovascular morbidity and mortality, especially since adipose tissue inflammation 
plays a pivotal role in all of these conditions. Indeed, the changes in the periaortic 
adipose tissue has huge implications for cardiovascular and myocardium health due to its 
close proximity. In addition, the researchers’ data on the effects of exercise and not 
caloric restriction on insulin-stimulated vasodilation of the aorta shows that exercise is 
able to induce insulin-sensitizing effects on vascular tissue while caloric restriction may 
not. 
 Exercise and caloric restriction both exhibit cardiovascular benefits and decrease 
the risks associated with CVD, inflammation, and other chronic conditions. However, it 
is unknown which intervention can improve cardiac dysfunction and inflammation 
associated with the cardiometabolic syndrome.  Investigating the comparative 
effectiveness of each of these interventions can elucidate more effective interventions 
during early pathology or provide new knowledge on the role of exercise or caloric 
restriction in heart health. Our study is novel as there are no studies to date that have 
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compared the effectiveness of each of these two interventions in an early overweight and 
insulin-resistant animal model, relative to changes in the myocardium. 
2.2.4 Specific Aims and Hypotheses 
 Cardiometabolic syndrome is becoming a worldwide epidemic, affecting about 
25% of the world population. Two of the underlying causes of cardiometabolic syndrome 
are obesity and insulin resistance. Cardiometabolic disease, along with obesity and 
insulin resistance, increases an individual’s risk of developing cardiovascular disease and 
dying from a cardiovascular event. Preventive care and lifestyle modifications such as 
diet and exercise are known to alleviate the rate of insulin resistance and obesity, thus 
diminishing the number of individuals suffering from cardiometabolic syndrome. Many 
of the adverse effects of cardiometabolic syndrome in the heart are due to the chronic 
inflammatory state of the disease. There exists a gap in the literature as to whether there 
are alterations to the myocardium in early stages of cardiometabolic syndrome and 
whether lifestyle interventions, in the form of exercise or caloric restriction, 
delay/prevent the development of cardiometabolic syndrome and CVD. 
AIM 1: To determine the effect of exercise and caloric restriction to change markers of 
cardiac dysfunction in a model of overweight and insulin resistance.   
Methods: OLETF rats will be separated into three groups (SED, EX, & CR). After 20 
weeks in each condition, heart tissue will be isolated and RNA will be extracted. 
Expression of genes related to the fetal gene program (i.e. α-MHC, β-MHC) and fibrosis 
(i.e. TGFβ1, Col-1, and COL-3) will be examined in each group.  
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Hypothesis 1:  Animals in the CR and EX group will exhibit lower expression of cardiac 
dysfunction genes compared with the SED group signifying CR and EX as effective 
countermeasures for pathological alterations in the heart in young OLETF rats.  
AIM 2: To determine the effect of exercise and caloric restriction to alter NF-κβ activity 
in the heart in an early model of overweight and insulin resistance. 
Methods: Nuclear and cytosolic fractions of OLETF heart tissue will be separated.  An 
NF-κB DNA-binding activity assay will be used to determine NF-κB activation in SED, 
CR and EX groups. 
Hypothesis 2: Sedentary animals will exhibit a greater activation of NF-κB in the heart 
compared to the CR and EX groups.  
AIM 3: To determine the effect of exercise and caloric restriction on gene expression of 
inflammatory markers related to NF-κβ activity and monocyte/macrophage infiltration in 
the heart in an animal model of early insulin resistance and obesity. 
Methods: Using RNA extracted in Aim 1, Polymerase Chain Reactions (PCR) will be 
conducted using primers for inflammatory genes such as TNF-α, IL-1β, MCP-1, in 
addition to monocyte and macrophage makers such as CD4, CD68, and F4/80, and 
determine their relative gene expression in the three conditions. 
Hypothesis 3: Exercise and Caloric restriction should exhibit lower expression of 
inflammatory genes that are related to NF-κβ signaling and immune cell infiltration 
compared with the sedentary group.  
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CHAPTER 3 
METHODS 
3.1 OLETF Animal Model and Characteristics 
 Otsuka Long-Evans Tokushima Fatty (OLETF) rats are spontaneous diabetic rats 
exhibiting polyuria (excessive urine production), polydipsia (excessive thirst), and mild 
obesity. This strain of rats was first discovered in 1984 from an outbred colony of Long-
Evans rats that was purchased from Charles River, Canada in 1982. The Tokushima 
Research Institute (Otsuka Pharmaceutical Co. Ltd., Tokushima, Japan) has maintained 
this particular diabetic strain of Long-Evans rat through selective breeding and named it 
Otsuka Long-Evans Tokushima Fatty rats.  Long-Evans Tokushima Rats (LETO) are the 
lean, non-diabetic counterparts to the OLEFT rats obtained through different original 
mating. However, both rats come from the same strain of Long-Evans rats. The LETO rat 
is commonly used as a genetic control group to the OLETF (Kawano et al., 1994; 
ChengD & Wang, M-W., 2005). 
 Otsuka Long-Evans Tokushima Fatty (OLETF) rats exhibit the following 
characteristics: 1) late onset hyperglycemia after 18 weeks of age, 2) chronic course of 
the disease, 3) mild obesity, 4) clinical onset of diabetes that is exhibited mostly in males, 
5) changes to pancreas and kidneys. Beginning at 5 weeks, the OLETF rat begins to 
rapidly gain weight, compared to their LETO counterparts. OLETF rats begin showing 
high blood glucose concentrations at 18 weeks and impaired glucose intolerance starting 
at 24 weeks of age. Plasma triglycerides concentrations start increasing at 8 weeks of age 
but cholesterol concentrations slightly increase after 40 weeks.  Along with these 
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changes, OLETF rats exhibit increased blood pressure at 18 weeks of age compared to 
LETO rats (Panchal et al., 2011).   
The clinical and pathological features of the OLETF rat closely resembles those 
exhibited in humans with Type 2 Diabetes Mellitus (ChengD & Wang, M-W., 2005). For 
our study, the OLETF rats were maintained until 20 weeks of age. At this time, the 
OLETF rat exhibits an overweight phenotype and early insulin resistance thus 
representing a pre-diabetic state. Since the animal model exhibits the clinical and chronic 
pathology of type 2 diabetes with mild obesity, this early time point is crucial in 
determining if there are early changes in the heart. Other animal models exhibit severe 
obesity with diabetes that may not be representative of what is exhibited in humans who 
may just be mildly obese and with insulin resistance.  
3.1.2 Animal Set Up 
 All animal protocols were approved by the University of Missouri Institutional 
Animal Care and Use committee.  For this experiment, male Otsuka Long-Evans 
Tokushima Fatty Rats (OLETF) were used and obtained at four weeks of age (Japan SLC 
Inc. 3371-8, Kotoh-Cho, Hamamatsu, Shizuoka, Japan) and were individually caged and 
maintained in temperature controlled (21°C) with light cycles from 6:00 to 18:00 hour 
and dark cycles from 18:00 to 6:00 hour. At 12 weeks, the rats were randomized into 
three groups: (I) sedentary (SED; n=10), (II) voluntary wheel running (WR; n=10) and 
(III) sedentary + diet restriction (DR, fed 70% of ad libitum-feed SED animals; n=10). 
Animals in the wheel running (WR) group were housed with running wheels connected 
to Sigma Sport BC 800 bicycle computer (Cherry Creek Cyclery, Fosters Falls, VA, 
USA) to determine daily running distance. All animals were provided with standard rat 
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chow (Formulab 5008, Purina Mills, St. Louis, MO) that consisted of approximately 26% 
protein, 18% fat and 56% carbohydrates. Sedentary and WR groups had ad libitum access 
to food. Body weights and food intakes were recorded on a weekly basis. At 20 weeks of 
age, the rats were sacrificed and anesthetized using intraperiotneal injection of 
pentobarbital sodium (50 mg/kg). Tissues were harvested after the animals were 
euthanatized by exsanguination in full compliance to American Veterinary Medical 
Association Guidelines on Euthanasia. Hearts were frozen and stored at -80oC until 
analysis. The wheels of the WR group were locked and food was removed from the cages 
of all groups approximately 14 hours before the rats were sacrificed (Crissey et al., 2014). 
3.1.3 Gene Expression/RNA Extraction 
 RNA was extracted from frozen cardiac tissue and homogenized using TRIzol 
reagent. The isolated RNA was then quantified using the Nanodrop 1000 
spectrophotometer and used to make 0.2 ug of cDNA using 5X iScript (BioRad). The 
primers used for the gene expression were designed and purchased from IDT. These 
primers were optimized using EvaSsofast (BioRad) to an efficiency of >90%. All gene 
expression analyses were ran in triplicate on the CFX96 RT-PCR machine with Rpl10a 
serving as control gene. 18S was originally tested as a house-keeping gene but was found 
to be expressed differently between our groups in the heart (figure 1A). We have found 
that Rpl10a is a suitable house-keeping/reference gene when performing RT-PCR with 
rat myocardium as it remains stable under the experimental conditions for these animals. 
mRNA expression values were analyzed via the ΔCT method whereby ΔCT = Rpl10a CT 
- gene of interest CT (Padilla et al., 2013).  mRNA levels are normalized to the SED 
group of rats, which was always set at 1 (Chrissy et al., 2014; Brattlelid et al., 2010). 
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 The genes that will be analyzed to determine cardiac dysfunction include: ANP, BNP, β-
MHC, and α-MHC in OLETF rats. ANP, BNP,β-MHC and α-MHC are members of the 
fetal gene program and their re-emergence in adult cardiac gene expression represents a 
pathological sign of cardiac dysfunction. CD4, a general T-cell marker is used to identify 
potential immune cell infiltration and genetic expression in the heart. CD68, a general 
marker of macrophages, was also used for this similar task. F4/80 is a marker for M1 
polarized macrophages that are involved in secreting pro-inflammatory biomarkers. 
COL1, COL3, and TGFβ1 are genes involved in the development of cardiac fibrosis. 
Lastly, MCP-1 IL-1β and TNF-α are genes involved in pro-inflammation and are known 
to have an effect in NF-κB activity. Rpl10a (F:5’-GAGGCGCATCTGATCCTAATC-3’, 
R:5‘-ATTTCTGCCCGCTGTCTATC-3’) was used as the reference gene for RT-PCR.  
 The full name and primers for the genes used are listed in table 1. Tables 2-4 include the 
genes that were studied, including primer sequences, as markers for inflammation, 
inflammatory cell infiltration, and fibrosis. 
 
Table 1. Names of Genes involved in Fetal Gene Programming 
Gene Name Full Name F (Forward) & R (Reverse) Primer 
sequence (5’-3’ direction) 
ANP Atrial Natriuretic Peptide F: TGCCGGTAGAAGATGAGGTC 
R: AGCCCTCAGTTTGCTTTTCA 
BNP Beta (Brain) Natriuretic 
Peptide 
F: CCCTTGGTTTGCTCTCAGAC 
R:AGGGGAGATGCTCAGAGTGA 
α-MHC Alpha Myosin Heavy 
Chain 
F: GCACTGAGGGGATAAGGTGA 
R: TTAGCCCAACCCAAAGTGTC 
β-MHC Beta Myosin Heavy 
Chain 
F:ACAAACCATGACCAACAGCA 
R: GGCTGTGGGGTTACTTCAGA 
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Table 2. Genes involved in inflammation 
Gene Name Full Name F (Forward) & R (Reverse) Primer 
sequence (5’-3’ direction) 
MCP-1 Macrophage Chemo-
attractant Protein-1 
F:AGCTGGGCATGACTGACATCT 
R:AGCCGACTCATTGGGATCAT 
IL-1β Interleukin 1β F:GACCTGTTCTTTGAGGCTGACA 
R:CTCATCTGGACAGCCCAAGTC 
TNF-α Tumor Necrosis Factor-
alpha 
F: AACACACGAGACGCTGAAGT 
R: TCCAGTGAGTTCCGAAAGCC 
 
Table 3. Genes involved with Fibrosis 
Gene Name Full Name F (Forward) & R (Reverse) Primer sequence (5’-3’ 
direction) 
COL1 Collagen Type 1 F:CTCTTTTAGGGACCCCAAGG 
R:GCTCCTCTCCCACTATGCAG 
COL3 Collagen Type 3-α F:GGGATCCAATGAGGGAGAAT 
R:TCCTGCTTCCAATCGACTTT 
TGF-β1  Transforming 
Growth Factor β1 
F: AAAGAATTCGGGGTTCGCGCTCTCCGAAG  
R:AAACTCGAGTTATCAGCTGCACTTGCAGGAG 
 
Table 4. Genes involved with monocytes and macrophages 
Gene Name Full Name F (Forward) & R (Reverse) Primer 
sequence (5’-3’ direction) 
CD4 Cluster of Differentiation 4 F: ACCCTAAGGTCTCTGACCCC 
R: TAGGCTGTGCGTGGAGAAAG 
CD68 Cluster of Differentiation 68 F:CTTGGCTCTCTCATTCCCTTAC 
R:CTGGTAGGTTGATTGTCGTCTC 
F4/80 EGF-like module-containing 
mucin-like hormone receptor-
like  
F: GCCATAGCCACCTTCCTGTT 
R: ATAGCGCAAGCTGTCTGGTT 
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3.1.4 NF-κB ELISA Assay  
 NF-κB analyses were performed on all three groups: caloric restriction (CR), 
wheel running (WR) and sedentary (SED) groups for a total of 30 subjects (n=10 in each 
group).  Nuclear extractions were prepared by homogenizing tissue samples using a 
commercial nuclear extraction kit (Nuclear Extraction Kit, Active Motif) according to the 
manufacturer’s instructions. Briefly, about 20-50 µg of frozen tissue was collected and 
crushed. While on ice, the crushed tissue was placed in a pre-chilled Dounce 
homogenizer and 400 µL of ice-cold 1X Hypotonic buffer containing phosphatase and 
protease inhibitors supplemented with DTT and detergent was added. Then a large-
clearance (A) pestle was used to disrupt tissue for about 2 minutes. The samples were 
incubated for 15 minutes on ice and centrifuged for 10 minutes at 850 x g at 4°C. Next 
the single cell slurry is subjected to a cell lysis protocol consisting of 200 µL 1X 
Hypotonic buffer was added to the slurry and allowed 15 minute incubation on ice to 
allow the cells to swell. 15 µL of detergent was then added and the cells were vortexed 
for 10 seconds at the highest setting. The suspension is then centrifuge for 30 seconds at 
14,000 x g in a microcentrifuge pre-cooled at 4°C. The supernatant was then transferred 
off to pre-chilled tubes (this supernatant contains the cytoplasmic fractionation) and the 
nuclear pellet is resuspended in 50 µL of Complete Lysis Buffer by pipetting up and 
down. The suspension is then incubated for 30 minutes on ice on a rocking platform set at 
150 rpm. Suspension was then vortexed for 30 seconds at the highest settings and 
centrifuged for 10 minutes at 14,000 x g in a 4°C pre-chilled microcentrifuge. The 
supernatant, containing the nuclear protein fraction, is pipetted off and stored at -80°C 
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and quantified. Total nuclear protein content was determined using a BSA-based protein 
quantification assay (ProStain; ActiveMotif, Carlsbad, CA, USA).  
 NF-κB activation was determined using the nuclear extracts, as described above, 
and an ELISA-based Trans AM NF-κB p65 assay kit (ActiveMotif, Carlsbad, CA, USA) 
according to the manufacturer’s directions. In short, 15 µg/µL of nuclear extract were 
added to wells coated with a consensus binding sequence for NF-κB (5’-
GGGACTTTCC-3’) and incubated for 1 hour at room temperature. Wells were then 
washed, and a primary antibody directed at the p65 subunit was added and left to 
incubate for 1 hour. This is followed by treatment of all wells with a secondary antibody 
conjugated to horseradish peroxidase. A subsequent colorimetric reaction is initiated with 
the addition of a developing solution for 5 min followed by the application of a stop 
solution. The absorbance of the plate is then read at 450 nm on a multiwall microplate 
reader (FLUOstar Optima, BMG Labtech, Offenburg, Germany). Wild-type and mutated 
consensus oligonucleotides were used as competitors for NF-κB binding to ensure 
specificity of the reaction as per the manufacturer’s instructions. All samples were run in 
duplicate, and the average value used for data analysis (LaBarbera et al., 2015; Hyldahl et 
al., 2011). 
3.2 Preliminary Data 
Data has been published previously on this cohort of animals by Crissey, et al 
(2014).  Figure 1 represents the OLETF rat characteristics at 5 weeks and at the end of 20 
weeks when the animals were sacrificed.  Changes in body composition in WR and CR 
groups were significant compared to the sedentary group, exhibiting lower percent body 
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fat and less visceral adipose tissue mass. Food intake increased from five weeks for all 
animal groups. The caloric restriction and sedentary group exhibited no changes in food 
intake after 12 weeks during the intervention period. The wheel running group exhibited 
fluctuations in food intake, with a decrease occurring around 14 weeks, which may be 
due to exercise effects. The relative food intake was approximately the same for all 
groups until during the intervention phase, where the WR group exhibited an increase 
relative to body weight. In addition, heart weight for both WR and CR were significantly 
different compared to the SED group. Heart weight to body weight ratio (HW/BW) was 
significantly different in the WR compared to SED while CR HW/BW ratio was 
significantly different compared to WR. Lastly, percent body fat for the WR was 
significantly different from the SED group and CR percent body fat was significantly 
different from the WR group. 
As summarized in table 5 (table 4 from Crissey et al., 2014) and described above, 
compared to the sedentary group, WR and CR plasma had lower triglycerides, total 
fasting cholesterol, LDL cholesterol, NEFAs, glucose and leptin. Lastly, the WR group 
exhibited improvements in HOMA-IR, lower plasma insulin and lower circulating MCP-
1 compared with sedentary rats (P< 0.05) (Crissey et al., 2014). Fasting plasma levels of 
IL-6, a marker of inflammation, were not different between SED, WR, and CR. However, 
TNF-α fasting plasma levels was statistically different between WR and CR (P< 0.05), 
with CR exhibiting higher fasting plasma level of TNF-α. Overall, the data from Crissey 
et al. shows that exercise and a 30% diet restriction regimen for 8 weeks was related to 
reduced adiposity, improved blood lipid profiles and systemic markers of insulin 
resistance in 20-week-old obese OLETF rats.  
44 
 
 
 
 
 
45 
 
CHAPTER 4 
RESULTS 
 
4.1 Reference Gene Quality Control 
 
 18S and RPL10a were evaluated for their appropriateness as control gene for RT-
PCR. Figure 1A and 1B show the average Ct values of 18S and RPL10a, respectively. 1-
way ANOVA revealed that18S Ct values were significantly different between groups. 
Post-hoc analysis showed that there were significant differences between CR vs. SED 
and CR vs. WR (p<0.001) but no differences between SED vs. WR. RPL10a Ct values 
showed no difference between groups as depicted in figure 1B and was therefore used as 
the reference gene for all RT-PCR gene expression analyses. 
 
4.1.2 Cardiac Dysfunction: Fetal Gene Expression and Fibrosis 
 
Figure 1. Ct values of RPL10a and 18S mRNA expression in cardiac 
tissue from caloric restriction (CR), wheel running (WR), and 
sedentary (SED) groups. (A) 18S Ct values from the means of 10 
different runs. (B) Rpl10a Ct values from one run. Values are 
expressed as means ± SE (n=10/group). * Denotes difference (p<0.05) 
from SED; † Denotes difference (p<0.05) from WR. 
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 To assess cardiac dysfunction in heart tissue of OLETF rats, we examined the 
pattern of α-MHC, β-MHC, ANP, BNP, TGFβ-1, collagen 1, and collagen 3 mRNA 
expression in the three different conditions (CR, WR, and SED). As shown in Fig. 2, 
there were no significant differences between groups in the mRNA expression of genes 
involved in the fetal gene program and in fibrosis; Fig. 2A, α-MHC (p=0.385); Fig. 2B, 
β-MHC (p=0.63); Fig. 2C, ANP (p=0.56); Fig. 2D, BNP (p=0.857); Fig. 2E, TGFβ1 
(p=0.323); Fig. 2F, COL1 (p=0.9), and Fig. 2G, COL3 (p=0.581).  
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Figure 2. Expression of genes related to cardiac dysfunction in caloric 
restriction (CR), wheel running (WR), and sedentary (SED) groups. α-
MHC (A), β-MHC (B), ANP (C), BNP (D), TGFβ-1 (E), Collagen 1 (F), and 
Collagen 3 (G) mRNA expression was measured by RT-PCR. Values are 
expressed as means ± SE (n=10/group). For each gene, SED is used as the 
reference group and set at 1. 
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Figure 3. NF-κB activation in cardiac tissue in caloric 
restriction (CR), wheel running (WR), and sedentary (SED) 
groups. Values are expressed as means ± SE (n=10/group).  
 
4.1.3 NF-κB Activation in Cardiac Tissue of OLETF rats 
 
 Nuclear extractions were performed on the cardiac tissue of OLETF rats in the 
WR, CR, and SED groups and used to determine p65 NF-κB activity. Figure 3 shows the 
values for the NF-κB activity of the WR, CR, and SED groups. There were no significant 
differences in NF-kB activity between groups. 1-way ANOVA showed that there was a 
trend for an overall effect of group (p=0.07) on NF-κB activation, with CR exhibiting 
greater NF-κB activation compared to SED (P=0.06). 
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 We examined the pattern for CD4, CD68, F4/80, MCP-1, TNF-α, and IL-1β 
mRNA expression in cardiac tissue of the CR, WR, and SED groups. As shown in Fig. 4, 
there were no differences in the mRNA levels of immune cell and NF-κB related target 
genes in the three different groups. Fig. 4A, CD4 (p=0.436); Fig. 4B, CD68 (p=0.402); 
Fig. 4C, F4/80 (p=0.603); Fig. 4D, MCP-1 (p=0.649); Fig. 4E, IL-1β (0.188) and Fig. 4F, 
TNF-α (p=0.745). 
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Figure 4. Expression of immune cell related and pro-inflammatory NF-κB genes 
of caloric restriction (CR), wheel running (WR), and sedentary (SED). (A) mRNA 
expression of CD4. (B) mRNA expression of CD68. (C) F4/80 mRNA expression. (D) 
MCP-1 mRNA expression. (E) IL-1β mRNA expression. (F) TNF-α mRNA 
expression. Values are expressed as means ± SE (n=10/group). For each gene, SED is 
used as the reference group and set at 1. 
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CHAPTER 5 
DISCUSSION 
 
 In this study, we aimed to determine effects of WR and CR to reduce markers of 
cardiac dysfunction, NF-κB activity, and gene expression related to NF-κB and immune 
cell infiltration compared with SED controls in 20 week old OLETF rats. Our major 
findings were: 1) there were no significant differences in markers of cardiac dysfunction 
between the groups, 2) there was a trend for increased NF-κB activity in the CR 
compared to the SED group and 3) there were no significant differences in the gene 
expression of markers related to immune cell infiltration and NF-κB target genes in the 
20 week old OLETF rats.   
Our data on cardiac dysfunction in OLETF rats complements and extends that of 
Yagi and colleagues (1997) in which cardiac dysfunction of OLETF rats were 
characterized over 54 weeks.  In this study, investigators examined pathological features 
of the heart and markers of cardiac complications in OLETF rats from the pre-diabetic 
state (14 weeks), non-insulin dependent diabetes mellitus (30 weeks) and insulin 
dependent diabetes mellitus (54 weeks), evaluating fetal gene expression and genes 
involved in cardiac fibrosis as markers for changes in cardiac performance. In addition, 
the Long-Evans Tokushima-Otsuka (LETO) rats were evaluated as the genetic control 
animals for the OLETF rats. The researchers found that there were no differences in fetal 
gene expression markers in OLETF rats between 14 weeks, at 30 weeks and that while a 
small difference in β-MHC was observed between OLETF and LETO at 30 weeks, larger 
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differences between OLETF and LETO in α-MHC, β-MHC, and ANP expression were 
only observed at 54 weeks.  This data indicates that changes in cardiac fetal gene 
program expression do not appear until later in the OLETF model. Therefore, although 
we did not have a LETO group for comparison, it is possible that we did not observe any 
differences between the groups because they were only 20 weeks old, which would not 
be long enough for SED animals to develop a fetal gene signature.  Further, fetal gene 
expression should not change with exercise, as it is not activated in normal physiological 
hypertrophy (Maillet et al., 2013). To our knowledge, there are no studies that have 
investigated the effects of CR on the fetal gene program.  However, since CR is known to 
attenuate insulin sensitivity in the heart of OLETF rats (Park et al., 2005) and improve 
cardiac energy metabolism (Dolinsky et al., 2010; Kemi et al., 2000), we would not 
anticipate that CR would also help maintain proper cardiac function and prevent an 
emergence of the fetal gene program. 
Interestingly, according to data from the same study (Yagi et al., 1997), there is 
evidence that cardiac fibrosis occurs at early time points in the OLETF model and that it 
may be related to inflammation.  Investigators reported that at 14 weeks of age, the left 
ventricular gene expression of collagen types I, III and IV, along with laminin, were 
significantly enhanced in OLETF compared with LETO rats of the same age. Collagen 
types III and IV and laminin mRNA levels remained elevated in OLETF rats at week 30 
compared to LETO. Transforming Growth Factor-β (TGF-β) is a pleiotropic cytokine 
that can regulate fibrogenesis and is released from pro-inflammatory cells (e.g. 
macrophages). The authors showed that mRNA levels of 14-, 30-, and 54-week-old 
OLETF rats were 1.5-, 1.6-, and 1.3-fold greater, respectively, than in the LETO rats 
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examined at those same time points. Thus, according to this study, markers of fibrosis are 
evident at as early as 14 weeks in the OLETF model when animals are overweight and 
insulin resistant.  We expected that markers of fibrosis would be lower in EX and CR 
groups compared with SED in our study in line with existing myocardial fibrosis 
suspected at 20 weeks (Mizushige et al., 2000).  Contrary to our hypothesis, we found no 
differences between groups in markers of fibrosis.  Since we do not have LETO control 
animals as a comparison, it is unknown whether the fibrosis occurs in the OLETF heart 
independent of CR and EX interventions.  
Caloric restriction and exercise are known to induce pleiotropic forms of 
cardiovascular protection (Dolinsky and Dyck, 2011; Shinmura et al., 2010). CR is able 
to increase longevity and reduce death due to chronic diseases such as cancer, T2DM, 
obesity, and cardiovascular disease.  Indeed, research has shown that CR is able to 
attenuate the production of ROS and oxidative damage by activation of SIRT1 and 
transcription factor NF-E2-related factor (Nrf2) (Csiszar et al., 2009). In addition, CR is 
able to attenuate age-related vascular inflammation by improving the NF-κB inhibition of 
pro-inflammatory gene transcription, thereby causing NF-κB to become active in anti-
inflammatory gene transcription and reducing a pro-inflammatory state (Weiss & 
Fontana, 2011). Lastly, like exercise, CR is able to reduce adiposity and inflammatory 
markers, especially in the cardiovascular system, leading to healthy cardiovascular 
function and can even decrease the adverse effects of cardiomyopathy (Weiss & Fontana, 
2011; Kemi et al., 2000).  
We hypothesized that the inhibitory effect of CR and EX on overall systemic 
inflammation in OLETF rats would be reflected in the heart and mediated through 
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inhibition of NF-κB’s pro-inflammatory factor transcription (Medeiros et al., 2011). 
Adiposity, especially in obesity and diabetes, exhibits paracrine and autocrine signaling 
of pro-inflammatory markers, thus leading to greater NF-κB activity and mRNA 
expression of pro-inflammatory markers in adipose tissue (Romacho et al., 2014). In the 
study conducted by Crissey and colleagues (2014), which analyzed the same animals as 
the present study, WR and CR in 20-week old OLETF rats showed lower gains in body 
weight over time, lower adipose tissue mass, and lower adipose tissue expression of 
inflammatory genes and markers of immune cell infiltration compared to the SED group. 
Furthermore, in periaortic adipose and aortic tissue, they reported lower expression of 
cytokines in WR and CR compared with SED.  Contrary to our second hypothesis our 
data showed a trend for increased NF-kB activity in CR compared with SED.  We also 
witnessed that there were no significant differences in the gene expression of markers 
related to immune cell infiltration and NF-κB target genes in the heart of these 20 week 
old OLETF rats, providing evidence that inflammation may not play a role in the heart at 
this time point. 
 The literature has focused mainly on the pro-inflammatory side of NF-κB and 
there is still a lack of information on the role of NF-κB on cardioprotection and anti-
inflammation in the heart. It is possible that our results could reflect the anti-
inflammatory and anti-apoptotic activity of NF-κB, though more research is needed. It 
has been shown that the anti-apoptotic activity of NF-κB depends on certain gene 
induction (Lui et al., 1996). NF-κB can induce the expression of cellular inhibitors of 
apoptosis (c-IAPs), caspase-8-c-FLIP (FLICE inhibitory protein), Bfl1, TNFR-associated 
factor (TRAF1) and TRAF2. TRAF1 and TRAF2 are adaptor proteins required in 
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optimizing NF-κB activity and it is postulated that their anti-apoptotic activity is most 
likely due to their ability in augmenting the activation of NF-κB (Karin & Lin, 2001). 
The c-IAPs proteins can directly bind and inhibit effector caspases, such as caspase-3 and 
caspase-7, and prevent activation of pro-caspase-6 and pro-caspase-9 (Deveraux et al., 
1998). These c-IAPs can thus inhibit apoptosis induced by both death receptors and 
mitochondria-dependent pathways. In particular, c-IAP1 and c-IAP2 expression by NF-
κB suppresses TNF-α mediated killing through inhibition of caspase-8 (Wang et al., 
1998). 
 There is data to suggest that NF-κB also inhibits apoptosis by DNA damaging 
agent, which act via the mitochondria-dependent pathway (Baldwin, A.S., 2001). This 
activity could be mediated through members of the Bcl-2 family, a family of pro- and 
anti-apoptotic proteins situated in the mitochondria, such as Bcl-χL and Bfl1. It appears 
that Bfl1 is able to induce its anti-apoptotic by preventing mitochondrial depolarization, 
the release of cytochrome c and caspase-9 activation (Wang et al., 1999). In addition, it is 
possible that Bcl-2 itself may be involved in the anti-apoptotic activity of NF-κB, as it is 
defective in cells that lack both c-Rel and RelA (p65), the major activating subunits of 
NF-κB (Grossman et al., 2000). However, more work is required to elucidate these 
proteins and their pathways in relations to the heart as these pathways have been studied 
most extensively in immune cells and oncogenesis. 
 Lastly, this study aimed to determine the comparative effectiveness of exercise 
and caloric restriction on inflammation and cardiac NF-κB signaling in 20 week old 
OLETF rats. From our results, it is difficult to state which of these two treatments is more 
effective in reducing inflammation and cardiac NF-κB activity. Data from Crissey et al., 
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shows that exercise is more effective in reducing fasting plasma levels of MCP-1, TNF-α, 
and other markers of obesity and diabetes (Crissey et al., 2014). In this regard, exercise is 
more effective than caloric restriction in attenuating the effects of inflammation and 
cardiometabolic syndrome parameters. Both caloric restriction and exercise have 
important roles in reducing inflammation, improving longevity, and reducing the risk for 
a multitude of diseases. In order to guide public health recommendations, more research 
is needed to determine which intervention is more effective in early progression of 
diseases such as diabetes and obesity.  Further, there is much debate on the effects of NF-
κB activity in relation to cardiovascular disease and function that warrants further 
investigation (Gordon et al., 2011).  
5.1 Limitations and Future Studies:  
A major limitation of this current study was the absence of tissue from LETO control 
animals for analysis. Since the OLETF rat is a genetic model of T2DM and mild obesity, 
a proper genetic control is needed to investigate and properly compare the effects of 
interventions such as caloric restriction, sedentary behavior, and exercise. Future studies 
require incorporation of LETO animals as a control group. Second, investigating the 
changes in the heart at different time points, 14 weeks and 30 weeks, can help provide a 
more complete picture of the effects of pre-diabetes on the hearts of OLETF rats. The 
literature has witnessed differences at 14 weeks and 30 weeks though there exists limited 
knowledge on WR and CR at these time periods.   Lastly, our analysis of NF-κB activity 
only provides information on the activation of NF-κB but warrants no information on 
what regions of DNA it is binding to. In future studies, NF-κB binding should be 
assessed using chromatin immunoprecipation (chIP) to determine what consensus 
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binding regions are being transcribed by NF-κB. Furthermore, microarray analysis on 
anti-inflammatory genes in cardiac tissues under the different interventions are warranted 
to see if there is a connection between NF-κB activity and these anti-inflammatory 
markers. 
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